Non-Hodgkin Lymphoma

Giving fewer courses of chemotherapy and no radiation could become a new standard for patients with stage 1 or 2 diffuse large B cell lymphoma based on the results of a recent study.

CAR-T cell therapy is drastically improving outcomes for patients with diffuse large B-cell lymphoma. However, the treatment can come with some severe side effects that patients need to know about.

Combining the immunotherapy Keytruda with a CAR-T cell therapy that targets the proteins CD19 and CD22 generates complete responses with minimal side effects, results from an early study demonstrate.

A recent approval of the combination of Monjuvi and Revlimid fills an unmet need for certain patients with DLBCL, according to Dr. Gilles Salles.

Heightening the dose of the targeted drug Rituxan (rituximab) during the first four cycles of the R-CHOP regimen does not improve outcomes in treating patients with diffuse large B-cell lymphoma, the phase 3 HOVON-84 trial found.

The agent, in combination with the current standard of care, is being evaluated as a frontline treatment for patients with high-risk Denovo Genomic Marker 1 (DGM1)–positive DLBCL.

The Food and Drug Administration approved Monjuvi in combination with Revlimid for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma.

Here are the top 5 CURE stories for July 2019.

This essay describes my journey with non-Hodgkin lymphoma — peripheral T-cell, not otherwise specified — and my most extraordinary nurse, Xuan Arnette, RN, OCN.

From landmark Senate legislation to the Pink Lemonade Stand Challenge, here’s what is making headlines in the cancer space this week.

The Food and Drug Administration approved Ruxience (rituximab-pvvr), a biosimilar to Rituxan (rituximab), for the treatment of certain adult patients with CD20-positive B-cell non-Hodgkin’s lymphoma and those with chronic lymphocytic leukemia.

Outwardly, you start to look like your old self again while inside you're still licking the wounds of your cancer battle.

How to conquer the fear of your own body, one step at a time.

WE SURVIVORS ARE INUNDATED with the message: “Be hopeful!” Unfortunately, that universal rallying cry doesn’t help us know how to find hope or what to hope for.

Long-term follow-up of the JULIET trial showed patients with relapsed or refractory DLBCL continued to experience durable responses 19 months after treatment.

Preventing febrile neutropenia is crucial because the body’s white blood cells help to fight infection.